Abstract. Intrauterine growth restriction (IUGR) has life-long health implications, yet there is no effective prenatal treatment. Daily intra-amniotic administration of insulin-like growth factor (IGF)-1 to IUGR fetal sheep improves fetal gut maturation but suppresses hepatic igf1 gene expression. Fetal hepatic blood supply is regulated, in part, by shunting of oxygen-and nutrient-rich umbilical venous blood through the ductus venosus, with the left hepatic lobe predominantly supplied by umbilical venous blood and the right hepatic lobe predominantly supplied by the portal circulation. We hypothesised that: (1) once-weekly intra-amniotic IGF-1 treatment of IUGR would be effective in promoting gut maturation; and (2) IUGR and its treatment with intra-amniotic IGF-1 would differentially affect igf1 and igf1r mRNA expression in the two hepatic lobes. IUGR fetuses received 360 mg IGF-1 or saline intra-amniotically once weekly from 110 until 131 days gestation. Treatment of IUGR fetuses with IGF-1 reversed impaired gut growth. In unembolised, untreated control fetuses, igf1 mRNA levels were 19% lower in the right hepatic lobe than in the left; in IUGR fetuses, igf1 and igf1r mRNA levels were sixfold higher in the right lobe. IGF-1 treatment reduced igf1 and igf1r mRNA levels in both lobes compared with IUGR fetuses. Thus, weekly intra-amniotic IGF-1 treatment, a clinically feasible approach, reverses the impaired gut development seen in IUGR. Furthermore, igf1 and igf1r mRNA levels are differentially expressed in the two hepatic lobes and relative expression in the two lobes is altered by both IUGR and intra-amniotic IGF-1 treatment.
Introduction
Intrauterine growth restriction (IUGR) is the failure of a fetus to achieve its intrinsic growth potential (Resnik 2002) and is a major cause of perinatal morbidity and mortality (Piper et al. 1996) . Babies of low birthweight carry an increased risk of developing obesity, high blood pressure, coronary heart disease, Type 2 diabetes, insulin resistance and impaired cholesterol metabolism in adult life (Godfrey and Barker 2000) . The increased risk of such diseases may be a consequence of permanent resetting of metabolic and homeostatic mechanisms resulting from an adverse intrauterine nutritional environment (Barker 1998) , an hypothesis supported by experimental data (Langley-Evans et al. 1996; McMillen and Robinson 2005) . Rapid postnatal growth (with upward crossing of centiles) of babies born IUGR occurs in most within the first 2 years of life (Saenger et al. 2007 ) and potentially may increase the risks of long-term disease (Ibáñez et al. 2006; Ong and Loos 2006; Leunissen et al. 2008; Rotteveel et al. 2008) . In 10-20% of babies born IUGR there is a lack of catch-up growth with reduced final height; this is associated with impaired cognitive neurodevelopment (Fattal-Valevski et al. 2009 ). Thus, an intervention during intrauterine life to prevent the effects of IUGR and postnatal growth perturbations may be the optimal strategy.
Clinical attempts to improve the growth of the fetus by maternal supplementation with protein (Kramer and Kakuma 2003) or oxygen (Battaglia et al. 1992) have not been successful. This may be because, in developed countries, placental insufficiency is one of the primary causes of IUGR, limiting delivery of nutrients and growth factors to the fetus (Robinson et al. 2000; Henriksen and Clausen 2002; Hendrix and Berghella 2008) . Experimental attempts to increase placental blood flow with sildenafil citrate in ovine pregnancies with growth-restricted fetuses resulted in adverse outcome (Miller et al. 2009 ) and supplementation with L-arginine (a precursor of nitric oxide) in pregnant women carrying severely IUGR fetuses had no effect on fetal growth (Winer et al. 2009 ). Therefore, a treatment that bypasses the placenta may provide the most promising approach.
Previously, we investigated such an approach in IUGR ovine fetuses, namely the administration of insulin-like growth factor (IGF)-1, one of the major growth factors for late-gestation fetal growth, into amniotic fluid (Bloomfield et al. 2002a; Eremia et al. 2007) . Daily administration of a low dose (20 mg) of IGF-1 reversed the delayed maturation of the gastrointestinal tract (GIT) seen in vehicle-treated IUGR fetuses (Bloomfield et al. 2002a) . We showed that IGF-1 administered into the amniotic fluid is taken up intact across the GIT and into the portal vein (Bloomfield et al. 2002b) and is thus delivered to the fetal liver. Gut igf1 mRNA levels were not altered by intra-amniotic IGF-1 treatment, although igf1r mRNA levels in the jejunum were increased (Shaikh et al. 2005) . In contrast, hepatic igf1 mRNA levels were reduced in the right lobe of the liver, consistent with downregulation by IGF-1 taken up across the gut and delivered to the liver via the portal vein (Shaikh et al. 2005) . A subsequent study, administering 120 mg IGF-1 into the amniotic fluid thrice weekly over a 4-week period, provided the first evidence of a treatment increasing fetal growth rate in IUGR fetuses in utero (Eremia et al. 2007) . However, for a treatment to potentially be useful clinically, the frequency of intra-amniotic injections would need to be significantly less than thrice weekly, with once-weekly injections perhaps being feasible.
Blood supply to the fetal liver is complex, with approximately 70-75% of the blood coming from the nutrient-and oxygen-rich umbilical venous (UV) blood, approximately 20% from the nutrient-and oxygen-poor portal venous (PV) blood, and the remainder from the hepatic artery (HA; Edelstone et al. 1978; Rudolph 1983) . The anatomy of the blood supply means that there is differential blood flow to the left and right hepatic lobes. In sheep, the left lobe receives over 90% of its blood from the UV, with approximately 6% and 1% from the HA and PV, respectively. In contrast, the right lobe receives only approximately 50% of its blood supply from the UV and the remainder from the PV (Edelstone et al. 1978) . Thus, the left lobe receives a considerably greater proportion of nutrient-and oxygen-rich blood from the placenta compared with the right lobe. Because IGF-1 is regulated by nutrient supply during fetal development (Oliver et al. 1993 (Oliver et al. , 1996 , we hypothesised that igf1 gene expression may differ in the two hepatic lobes.
Furthermore, in IUGR pregnancies there is a redistribution of blood supply from the periphery to 'essential' organs, such as the heart and brain, due to fetal hypoxia (Thornburg and Morton 1994) . Shunting UV blood through the ductus venosus (DV), thereby bypassing the liver and delivering nutrient-rich blood to the systemic circulation, is one mechanism of redistributing cardiac output, which may contribute to 'brain sparing' seen in IUGR fetuses. Studies in ovine fetuses have demonstrated an increased ductal shunt during acute hypoxia induced by either reducing inspired maternal oxygen concentrations or by umbilical arterial occlusion (Edelstone et al. 1980; Tchirikov et al. 1998; Kiserud et al. 2000a) . Studies in human IUGR fetuses suggest that a similar phenomenon is seen in these fetuses, which are typically hypoxaemic and hypoglycaemic (Weiner et al. 1996; Bellotti et al. 2006; Kiserud et al. 2006) . Moreover, fetal growth may be partly regulated by hepatic blood perfusion (Tchirikov et al. 2002) and a reduction in hepatic perfusion may have lasting consequences on the metabolic adaptation of the liver, potentially affecting health in later life (Kiserud et al. 2006) . We therefore hypothesised that if IUGR alters the proportion of nutrient-rich UV blood being shunted through the DV, it may affect igf1 gene expression in the two hepatic lobes differently. Finally, administration of exogenous IGF-1 into the amniotic fluid, and thereby into the PV, may also affect gene expression differently in the hepatic lobes via direct downregulation or indirectly via effects on DV shunting as a result of the vasoactive effects of IGF-1 (Haylor et al. 1991; Wu et al. 1994) .
Therefore, the aims of the present study were, first, to determine whether a more clinically applicable regimen for intra-amniotic IGF-1 treatment of IUGR (reducing the treatment frequency from thrice to once weekly) would still promote the growth and development of fetal GIT morphology and affect igf1 and igf1r gene expression in the fetal gut. Second, we wanted to determine the effects of IUGR and intra-amniotic IGF-1 treatment on mRNA levels of igf1 and igf1r in the left and right hepatic lobes of ovine fetuses.
Materials and methods

Animals
Twenty-seven pregnant Romney ewes carrying Dorset crossbreed singleton fetuses were housed in individual cages with free access to water and pelleted food. All animal experiments were approved by the University of Auckland Animal Ethics Committee and were conducted in accordance with the National Animal Ethics Advisory Committee guidelines (National Animal Ethics Advisory Committee 2002).
Surgery
After acclimatisation to laboratory conditions, animals underwent surgery under halothane anaesthesia at 98 days of gestation (dGA; term ¼ 147 dGA). Streptopen (250 mg procaine penicillin and 250 mg dihydrostreptomycin sulfate; Pittman Moore, Upper Hutt, New Zealand) was administered intramuscularly before surgery. Chronic indwelling catheters were inserted into a tarsal artery and vein, the amniotic sac (two catheters), a maternal femoral artery and vein, and a maternal carotid artery and jugular vein. In ewes randomised to induction of IUGR, additional catheters were inserted into both maternal uterine arteries (UA). Growth catheters were inserted subcutaneously around the fetal chest using established techniques (Harding et al. 1997; Eremia et al. 2007 ).
Experimental design
Sheep were randomly assigned to one of three experimental groups, namely control fetuses (n ¼ 11), which were unembolised and untreated, and two IUGR groups, treated with either saline (IUGR; n ¼ 9) or IGF-1 (IGF-1; n ¼ 7). In the two embolised groups, UA embolisation to induce IUGR, performed as described previously by Bloomfield et al. (2002c) and Eremia et al. (2007) , commenced at 103 dGA and continued for 7 days. Briefly, 20-50 mm polystyrene microspheres (Superose 12 diluted 1 : 100 to give approximately 1-2 Â 10 5 beads mL À1 ; Pharmacia Biotech, Uppsala, Sweden) were injected once or twice daily into the UA catheters, with the dose adjusted according to the fetal blood gases and daily girth increment (Bloomfield et al. 2002c; Eremia et al. 2007) . Embolisation was omitted if the fetal arterial P a O 2 was o16 mmHg, the fetal lactate concentration was 42.0 mM or if growth catheters had not shown an increase for 2 consecutive days. Following completion of embolisation, IUGR fetuses received intra-amniotic injections of either 360 mg (100 mg mL À1 ) IGF-1 (Genentech, San Francisco, CA, USA; IGF-1 group) or an equivalent volume of sterile saline (IUGR group) on 110, 117 and 124 dGA.
Post mortem
Ewes were killed with an overdose of sodium pentobarbitone on 131 dGA. The uterus was removed, incised and the umbilical cord clamped. The fetus was removed, dried, weighed and measured. The fetal liver, GIT and brain were rapidly removed and weighed. The GIT was then divided into the stomach and small and large intestines and each part was weighed and measured separately. Sections of the stomach (half way along the length of the abomasum), duodenum (first 10 cm of the small intestine), jejunum (10 cm distal to the duodenojejunal junction) and ileum (10 cm proximal to the ileocaecal valve) were opened longitudinally and the bowel contents removed. Samples were rapidly frozen in liquid nitrogen and stored in sterile vials at À808C for molecular analysis or pinned onto a cork mat with the villi facing upwards and immersed in 10% buffered formalin for later histological analysis. Liver tissue was collected from the right (1 cm to the right of the gall-bladder) and left (half way between the DV and the left margin of the liver) lobes and rapidly frozen.
Real-time polymerase chain reaction to determine igf1 and igf1r mRNA levels Total RNA was extracted by the Trizol method (Invitrogen, Carlsbad, CA, USA). Each RNA sample was diluted 10-fold in 10 mM Tris (pH 7.0, RNAse free). The concentration of each RNA sample was measured using a NanoDrop spectrophotometer equipped with 3.0.1 NanoDrop software (ND-1000 Spectrophotometer; BioLab, Auckland, New Zealand).The ratio of absorbance at 260 : 280 nm was used to assess RNA purity. First-strand cDNA was synthesised using the Superscript III first strand synthesis system (Invitrogen) according to the manufacturer's instructions. RNA samples were treated with RNase-free DNase I (Invitrogen) before real-time polymerase chain reaction (PCR) to eliminate any potential genomic DNA. Transcript abundance was determined by real-time PCR using TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA, USA). The PCR amplifications of the igf1 and igf1r gene transcripts were performed in triplicate on an ABI Prism 7900HT Sequence Detector (Applied Biosystems) using standard cycling conditions recommended by the manufacturer (508C for 2 min, 958C for 10 min, followed by 40 cycles of 958C for 15 s and 608C for 1 min). Singleplex amplification was performed in 384-well plates with a total reaction volume of 20 mL, containing 10 mL TaqMan Universal PCR Master Mix (Applied Biosystems, Branchbury, NY, USA), 1 mL cDNA template, 200 nM probe, 900 nM forward and reverse primers and 6 mL diethylpyrocarbonate (DEPC)-treated water. Standard curves of the target gene and 18S were included in each plate, consisting of 10-fold serial dilutions of cDNA synthesised from a randomly chosen fetal liver sample with good RNA quality. Real-time PCR efficiencies were calculated from the slopes of the standard curves for each target gene using the equation: E ¼ 10 (À1/slope) (Pfaffl 2001) . Comparisons of mRNA levels between groups was performed according to Pfaffl (2001) , expressing one group relative to another and as a ratio to relative 18S rRNA levels, used as a housekeeping gene, with 99% confidence intervals (CI) generated around the ratio to account for multiple testing (Bloomfield et al. 2006) . Probe and primer sequences were as published previously (Bloomfield et al. 2006) . Primers sequences for igf1 cover the end of exon 3 and those for igf1r are specific for the b-subunit.
Western blotting for determination of IGF-1 and IGF-1 receptor protein levels Protein was extracted from tissues, quantified, separated electrophoretically, transferred to nitrocellulose membranes and non-specific binding blocked as described previously (Shaikh et al. 2005) . Blots were then incubated with anti-IGF-1 and anti-IGF-1 receptor (IGF-1R) antibodies, as described previously (Bloomfield et al. 2006) , except that the anti-IGF-1 antibody was used at a dilution of 1 : 500. Secondary antibodies were as described previously (Bloomfield et al. 2006) . In addition, specific protein bands were detected and captured as described previously (Shaikh et al. 2005) . Densitometric analysis of the immunoblots that were visualised on autoradiographic film was performed on a GS800 densitometer (Bio-Rad, Hercules, CA, USA) using Quantity One software (Bio-Rad). Membranes were then stripped and processed for the detection of b-actin as described previously (Bloomfield et al. 2006 ), but using a 1 : 50 000 dilution of the primary antibody. All signals are expressed as optical densities relative to the signal for b-actin.
Histology
To confirm whether weekly treatment with IGF-1 had a similar effect on mucosal growth in the small intestine as daily treatment (Bloomfield et al. 2002a ), we measured villus height, crypt depth, submucosal thickness and muscularis thickness in the jejunum, the region of the GIT that we have reported previously was most responsive to intra-amniotic IGF-1 treatment (Bloomfield et al. 2002a) . Longitudinal sections of the jejunum were embedded in paraffin and 5 mm sections were cut, mounted onto poly-L-lysine-coated glass slides (Biolab Scientific, Auckland, New Zealand) and stained with haematoxylin and eosin. Image analysis was performed on a light microscope (Carl Zeiss Microimaging, Thornwood, NY, USA) using AxioVision software (version 3.1.1.1) and an AxioCam HRc camera (Carl Zeiss Microimaging). For each fetus, 12 measurements were made from each of two sections of jejunum for each of the parameters listed above, with the mean of the 24 measurements used in subsequent analyses.
Statistics
Data for real-time PCR are expressed as relative expression ratios to the control group with 99% confidence intervals to account for multiple comparisons between groups. Non-PCR data were compared by analysis of variance (ANOVA) in Minitab (version 15; University Park, Pennsylvania State University, State College, PA, USA), with data transformed by the Box-Cox method (Box and Cox 1964) as required. Pairwise comparisons between the groups were performed using Tukey's simultaneous tests. The significance level for these analyses was set at the 5% level.
Results
Fetal size and organ weights
Consistent with previous studies (Bloomfield et al. 2002a; Eremia et al. 2007) , embolised fetuses were hypoxic, polycythaemic and hypoglycaemic (data not shown). Embolisation reduced fetal bodyweight by 21% (P o 0.05; Table 1 ) and increased the brain : bodyweight ratio by 17% (P o 0.05; Table 1 ), consistent with a brain-sparing effect. Other organ weights were not significantly different between groups (Table 1) . Histological analysis of the jejunum showed that embolisation decreased the thickness of the submucosa and muscularis externa and increased villus height, thus also increasing the villus height : crypt depth ratio ( Table 2) .
Treatment of IUGR fetuses did not alter fetal bodyweight or size (Table 1) and had no significant effect on organ weight (Table 1) . However, IGF-1 treatment significantly decreased villus height and the villus height : crypt depth ratio, and significantly increased the thickness of the submucosa and muscularis externa compared with IUGR fetuses such that these values did not differ significantly from those found in control fetuses (Table 2) . Gene and protein expression in the GIT Embolisation reduced igf1 mRNA levels in the stomach by nearly half (P ¼ 0.01), but there were no differences in igf1 expression in other GIT regions (Table 3) . IGF-1 treatment resulted in increased igf1 mRNA levels in the stomach compared with IUGR fetuses, although levels remained significantly lower than in control fetuses (Table 3 ). In the duodenum, IGF-1 treatment resulted in significantly lower igf1 mRNA levels compared with IUGR fetuses (Table 3 ). In contrast, in the jejunum, igf1 mRNA levels were increased by 4.0-and 3.6-fold compared with control and IUGR fetuses, respectively (Table 3) . Embolisation had no effect on igf1r mRNA levels in the GIT (Table 3) . However, intra-amniotic IGF-1 treatment increased igf1r mRNA levels in the ileum compared with control fetuses (Table 3) . IGF-1 treatment had no effect on igf1r mRNA levels in the jejunum.
Embolisation had no significant effects on IGF-1 or IGF-1R protein levels in the GIT (Table 4) . IGF-1 treatment significantly increased IGF-1 levels in the ileum compared with controls (Table 4) .
Gene and protein expression in the two hepatic lobes
In control fetuses, igf1 mRNA levels in the right hepatic lobe were 19% lower than in the left lobe, but igf1r mRNA levels were similar (Table 5 ). In IUGR fetuses, igf1 and igf1r mRNA levels in the right lobe were 6.3-fold higher than in the left lobe (Table 5) . Thus, in IUGR fetuses, igf1 and igf1r mRNA levels were significantly higher in both the right and left hepatic lobes than in control fetuses (Table 3) . Treatment of IUGR fetuses with IGF-1 significantly reduced igf1 and igf1r mRNA levels in both the right and left hepatic lobes compared with saline-treated embolised fetuses (Table 3) . The igf1 and igf1r mRNA levels in the right hepatic lobe of IGF-1-treated fetuses were 2.5-and 1.7-fold higher, respectively, than in the left lobe (Table 5) . However, although igf1 mRNA levels in the right hepatic lobe of IGF-1 fetuses were 2.5-fold higher than those in the control group, igf1 mRNA levels in the left hepatic lobe were comparatively reduced (Table 3) .
Overall, IGF-1 protein levels were higher in the left hepatic lobe than the right lobe, and IGF-1R protein levels were higher in the right lobe than the left (Fig. 1) . In the left lobe, IGF-1 protein levels were significantly higher in the IGF-1-treated group than in controls (Fig. 1) . The IGF-1 protein levels in the right lobe and IGF-1R protein levels in either lobe did not differ significantly between the groups (Fig. 1) .
Discussion
We have shown previously that daily administration of 20 mg IGF-1 into the amniotic fluid for 10 days in late gestation results in a marked increase in growth of the GIT mucosa (Bloomfield et al. 2002a) . In a subsequent study, we reported that extending the duration of treatment to 4 weeks, with thrice-weekly intraamniotic administration of 120 mg IGF, improved fetal growth rates (Eremia et al. 2007) . In the present study, we have extended the treatment interval to once weekly while still giving the same total weekly dose as used previously (Eremia et al. 2007) and have demonstrated that this treatment regimen still results in reversal of the adverse effects on GIT mucosal growth and development seen in IUGR. Interestingly, this reversal of the effects of IUGR on the fetal GIT occurs in the absence of any significant change in fetal weight. It is possible that other effects of IUGR may have also been altered in the absence of a change in fetal weight. For example, we have demonstrated previously that fetuses of ewes undernourished in the periconceptional period have reduced fetal growth trajectory in late gestation Table 5 . igf1 and igf1r mRNA levels in the right hepatic lobe compared to the left hepatic lobe within each treatment group Data are given as fold changes, with 99% confidence intervals in parentheses. IUGR, intrauterine growth restriction; IGF-1, insulin-like growth factor-1 
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Reproduction, Fertility and Developmentwithout altered size at birth compared with fetuses of ewes that were well fed throughout (Oliver et al. 2005) . However, fetuses with reduced growth trajectory go on to have impaired glucose tolerance postnatally (Todd et al. 2009 ). Thus, increasing fetal growth trajectory in IUGR fetuses may have beneficial longterm consequences, both on GIT development, as shown here, and potentially on metabolism, without a change in size at birth. The long-term consequences of intrauterine treatment of IUGR now need to be determined. Should this approach be shown to be safe and with beneficial long-term effects, a once-weekly treatment would be a feasible clinical approach.
Gut
Embolisation had little effect on igf1 and igf1r mRNA and protein levels in the fetal GIT, with only igf1 mRNA levels in the stomach being decreased. IGF-1 treatment suppressed igf1 mRNA levels in the stomach, but increased igf1 mRNA levels in the jejunum and IGF-1 protein levels in the ileum, and increased igf1r mRNA levels in the stomach. These findings differ from those of our previous study, in which IUGR resulted in decreased igf1 and igf1r mRNA levels in the jejunum and IGF-1 increased igf1r mRNA levels throughout the GIT (Shaikh et al. 2005) . Differences between the two studies are likely the result of variations in experimental protocols. Previously, fetuses were treated with 20 mg IGF-1 injected into the amniotic fluid on a daily basis for 10 days, commencing at 110 dGA, with tissues being collected 24 h after the last dose (Shaikh et al. 2005) . In the present study, fetuses were treated with once weekly doses of 360 mg IGF-1 from 120 dGA, with tissues collected 7 days after the last dose. The half-life of IGF-1 in amniotic fluid is 24 h and significant amounts are still present for several days after dosing (Bloomfield et al. 2002b) . Because the total weekly dose in the present study is more than twice that used previously, downregulation of igf1 and igf1r in the proximal GIT is not unexpected. Changes in the distal small intestine may reflect systemic or local effects of IGF-1 treatment.
There was no significant effect of IGF-1 treatment on GIT weight and length. However, the effects on intestinal morphology were similar to those we reported previously (Bloomfield et al. 2002a) . Impairment of GIT development in IUGR fetuses may lead to severe health outcomes, such as delays in establishing enteral feeding, postnatal growth failure and, particularly in developing countries, an increased risk of infection from bacterial translocation across the GIT epithelium (Lunn et al. 1991; Prindull and Ahmad 1993) . Gastrointestinal permeability may also be permanently altered in infants born IUGR (Lunn et al. 1991) . Supplementation of formula with IGF-1 (10 mg per 100 mL) in preterm babies, some of whom were IUGR, did not increase postnatal growth, but gut permeability was decreased (Corpeleijn et al. 2008) . These studies emphasise that the postnatal period is not the optimal window for treatment of impaired GIT maturation. In contrast, we have demonstrated that antenatal supplementation of IGF-1 in IUGR ovine fetuses reverses the delayed maturation and impaired morphology of the GIT seen in IUGR fetuses. If the effect on morphology is translated into function, this treatment could mitigate common postnatal morbidities in IUGR infants.
Liver
In the present study, we report for the first time that mRNA and protein levels of igf1 differ in the two hepatic lobes of ovine fetuses. This is consistent with the differential blood supply to the two lobes and with a previous report demonstrating differential regulation of numerous genes in the hepatic lobes of baboons in mid-gestation (Cox et al. 2006) . Further, we showed that both IUGR induced by placental embolisation and its treatment with intra-amniotic IGF-1 differentially affect the expression of igf1 and IGF-1R in the two hepatic lobes. These data suggest that the amniotic fluid is a potential route for interventions targeting both GIT growth and hepatic development.
The higher igf1 and igf1r mRNA levels in the left hepatic lobe compared with the right in control fetuses is consistent with blood supply to the left lobe being almost exclusively oxygenand nutrient-rich UV blood, whereas the right lobe receives mostly oxygen-and nutrient-depleted blood (Edelstone et al. 1978) . This difference is secondary to shunting of UV blood through the DV, thereby bypassing the right hepatic lobe, which therefore receives a significant proportion of its blood supply from PV drainage. In fetal lambs 38-64% of the umbilical blood is shunted through the DV Rudolph et al. 1991) ; in human fetuses, similar shunting has been estimated at 45% at 20 weeks and 15% at term (Pennati et al. 1998; Kiserud et al. 2000b; Bellotti et al. 2004) .
The liver is likely to have an important role in fetal growth, being the first organ to receive nutrient-rich oxygenated blood from the placenta (Tchirikov et al. 2002) . It has a role in the synthesis and metabolism of macronutrients (Seifter and Englard 1994) , as well as in the synthesis of IGF-1 (Sjögren et al. 1999; Ohlsson et al. 2009 ). When DV shunting was increased experimentally (and thus hepatic perfusion decreased) by implantation of a stent into the DV, cell proliferation in the liver, heart and skeletal muscle of ovine fetuses was reduced (Tchirikov et al. 2002) . In contrast, increased hepatic perfusion led to greater igf1 and igf2 mRNA expression in the liver (Tchirikov et al. 2002) . These data suggest a potential role of hepatic perfusion in fetal growth. Blood flow through the DV is increased during acute hypoxia in both human and ovine fetuses (Edelstone et al. 1980; Reuss and Rudolph 1980; Rudolph et al. 1991; Tchirikov et al. 1998; Kiserud et al. 2000a) . In severely IUGR fetuses, greater shunting of UV blood flow through the DV provides a relatively constant flow to the heart and brain at the expense of fetal hepatic perfusion from the DV (Bellotti et al. 2004; Kiserud et al. 2006) . This shunting may be mediated, at least in part, via fetal responses to intrauterine stress (Cohen et al. 1982; Jensen and Berger 1993; Bellotti et al. 2004 Bellotti et al. , 2006 .
It would be expected that this increased shunting of UV blood through the DV would result in decreased hepatic expression of nutrient-responsive genes, such as igf1. Decreased hepatic expression (the hepatic lobe sampled is not stated) of igf1 has been reported previously in studies in which IUGR was induced by prepregnancy carunclectomy in the ewe, resulting in restricted placental size (Gentili et al. 2009 ). This results in chronic hypoxia and fetuses of varying size. Interestingly, decreased hepatic igf1 expression was only seen in fetuses that also had reduced liver growth. In IUGR fetuses with preserved liver growth, igf1 mRNA levels did not differ from that in controls (Gentili et al. 2009 ). In contrast, in the present study, igf1 mRNA levels in both hepatic lobes increased among the saline-treated IUGR fetuses compared with the controls. The much greater increase in the right hepatic lobe compared with the left (eightfold) suggests that these differences may be related to differential blood flow to the two hepatic lobes. In severe IUGR, the increased shunting of blood via the DV may lead to a reversal of blood flow in the left portal vein, with PV blood then contributing a much greater proportion of the blood supply to the left hepatic lobe than is usually the case (Kilavuz et al. 2003; Kessler et al. 2007 Kessler et al. , 2009 ). Furthermore, the decreased hepatic blood supply from the UV may be compensated for by an increased contribution from the hepatic arteries, which would supply both hepatic lobes (Kilavuz and Vetter 1999) .
Finally, it is known that the fetal GIT can supply a significant proportion of the fetal nitrogen requirement in late gestation (Gitlin et al. 1972) and that this uptake increases with addition of supplementary amino nitrogen into the fetal GIT (Charlton and Reis 1981) . Therefore, it is possible that, in the face of impaired placental supply, IUGR fetuses increase GIT utilisation of amino acids, including from the amniotic fluid. Our preliminary data suggest that this may indeed be the case in IUGR induced by placental embolisation (Bloomfield et al. 2002c) . Thus, in IUGR there may be an increase in the proportion of blood supply to both hepatic lobes from hepatic arterial blood, an adjustment of the relative proportions that each hepatic lobe receives from PV blood and potentially altered nutrient supply from the GIT. Together, these changes could account for the increased igf1 mRNA levels in both hepatic lobes reported here.
Another possible explanation for the upregulation of hepatic igf1 and igf1r mRNA levels following IUGR is that in this paradigm, which reflects relatively acute placental insufficiency, there may be an initial hepatic sparing at the expense of brain sparing (Haugen et al. 2005) . However, our previous finding of reduced hepatic weight following a similar protocol (Bloomfield et al. 2002a ) and the tendency to reduced hepatic weight in the present stud, makes this explanation unlikely.
The reduction in igf1 mRNA levels with IGF-1 treatment is consistent with our previous study (Shaikh et al. 2005) . In the present study, igf1 mRNA levels decreased in both hepatic lobes, consistent with a systemic effect or downregulation in response to IGF-1 delivery via the portal system, which, as outlined above, may supply both hepatic lobes in IUGR. The magnitude of the effect is different in the two hepatic lobes, perhaps more in keeping with an effect mediated via the portal circulation. This could be either a direct effect of absorbed IGF-1, supported by increased IGF-1 protein levels because the antibody detects both human and ovine IGF-1, or via a GIT-derived mediator, such as ghrelin, or an incretin, such as glucagon-like peptide 1.
Conclusion
Treatment of IUGR fetuses with IGF-1, given as a weekly intraamniotic injection, results in reversal of the impaired GIT development seen with IUGR, along with altered expression of igf1 and igf1r. The potential postnatal effects of this treatment warrant further investigation to determine whether intraamniotic IGF-1 can translate into an effective clinical treatment for severely growth-restricted fetuses. Such studies should address both the immediate perinatal morbidities, including GIT function, and longer-term outcomes. In addition, both IUGR and its once-weekly treatment with intra-amniotic IGF-1 have differential effects on the expression of igf1 and igf1r mRNA in the two hepatic lobes of ovine fetuses. The patterns of expression, together with existing literature, suggest that differences in the development of the two hepatic lobes during fetal life likely relate to the complex blood supply to the fetal liver and its regulation in IUGR. These data are relevant for the study of hepatic gene expression in the fetus and potentially for understanding the long-term effects of IUGR on later hepatic function.
